AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03720847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol Transdermal Patch 0.1 mg/24 hrs
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
Study NCT03720847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone
Description: 100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation
Study NCT03720847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Micronized Progesterone
Description: 100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation
Study NCT03720847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive Clear Patch
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
Study NCT03720847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Clear Patch
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
Study NCT03720847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Study NCT03720847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Study NCT03975634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Stimulation
Description: Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
Study NCT01710085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011
Description: Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
Study NCT04109963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
Study NCT02785042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis OCT
Description: OCT imaging
Study NCT02078466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of functional ability and follow-up at home
Description: Assessment of functional ability and follow-up at home
Study NCT02734667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM at diagnosis of T1D
Description: Initiation of non-adjunctive CGM use at diagnosis of T1D
Study NCT01610193 — intervention group
Intervention type: PROCEDURE
Intervention: Appendicectomy
Description: Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
Study NCT03834012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone 800 µg per day
Description: Intervention: Drug: Beclomethasone 800 µg HFA per day
Study NCT03834012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention: Drug: placebo
Study NCT03834012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention: Drug: placebo
Study NCT03834012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone 400 µg per day
Description: Intervention: Drug: Beclomethasone 400 µg HFA per day
Study NCT03834012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone 640 µg per day
Description: Intervention: Drug: Beclomethasone 640 µg per day
Study NCT01718496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
Study NCT01718496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
Study NCT01718496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: patients with advanced COPD on the other study arm will randomly receive Placebo
Study NCT01718496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients with advanced COPD on the other study arm will randomly receive Placebo
Study NCT02594111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine vs Placebo
Description: Colchicine vs Placebo 1.8 mg PO over 1 hour
Study NCT02594111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine vs Placebo
Description: Colchicine vs Placebo 1.8 mg PO over 1 hour
Study NCT00662259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam (Xanax)
Description: Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
Study NCT00662259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, bid, p.o. for 28 +/- 2 days.
Study NCT04250480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Description: beta-alanine tablet
Study NCT04250480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: rice powder tablet
Study NCT02323438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Brand Cigarette
Description: Combustible cigarette brand style smoked most frequently by subject
Study NCT02323438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #1
Description: Electronic cigarette
Study NCT02323438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #2
Description: Electronic cigarette
Study NCT02323438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leading U.S. Nicotine Gum
Description: 4 mg nicotine polacrilex gum
Study NCT01653418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT01653418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Study NCT01653418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT01653418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT01653418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT01653418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Study NCT02737618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trojan Chameleon Personal Lubricant
Description: silicone base with sensate
Study NCT02871362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AS-118
Description: Take one a day
Study NCT02871362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one a day
Study NCT05203016 — intervention group
Intervention type: OTHER
Intervention: Hipotermia/Normotermia
Description: The temperature will be measured at the beginning and at the end of the surgery, as well as during admission to the Post-Anesthesia Care Unit, where the temperature normalization time will be noted in the event of hypothermia. In retrospect, those variables corresponding to the late postoperative period will be evaluated and the telephone interview will be conducted to assess the quality of care received. All the data will be reflected in the collection booklet that we present in the annex.
Study NCT01324752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 and Losartan with Food
Description: The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
Study NCT01324752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No PA21; Losartan with food
Description: The maximum dose of Losartan will be 100 mg/day.
Study NCT01324752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 with food and Losartan 2 hours later
Description: The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
Study NCT04678674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth root augmentation
Description: Autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement.
Study NCT02840565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
Study NCT00486863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: 60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.
Study NCT00486863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Made with the same color coded gelatin capsules with the inert compound dextrose.
Study NCT02840565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
Study NCT03870386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-BD with LAMS
Description: Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy
Study NCT03870386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
Study NCT02303054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar Radiofrequency Focal Ablation
Description: Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
Study NCT04234217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)
Study NCT04234217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: Suppression of lipolysis by niacin infusion
Study NCT05589493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis
Description: A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by dental implants following the All-on-4 Concept arrangement.
Study NCT00968266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-centered group intervention
Description: Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent.
Study NCT02931097 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulating deep brain electrodes and pulse generator
Study NCT02931097 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Study NCT01143792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA) + HIV prevention
Description: 12 sessions of the CRA and 2 sessions of HIV prevention.
Study NCT01143792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management + HIV Prevention
Description: 12 sessions of case management and 2 sessions of HIV prevention.
Study NCT01143792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET) + HIV prevention
Description: 2 sessions of MET and 2 sessions of HIV prevention.
Study NCT01859819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT01859819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IT Cytarabine
Study NCT00968266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered group intervention
Description: Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent.
Study NCT00525291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation
Description: In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
Study NCT00525291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-biofeedback alone
Description: In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
Study NCT02561897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Study NCT02561897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT04865848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental local anesthesia
Description: Dental local anesthesia
Study NCT04865848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental local anesthesia
Description: Dental local anesthesia
Study NCT00885443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
Study NCT00885443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
Study NCT03701191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inverted periosteal pedicle flap
Description: The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
Study NCT03701191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverted periosteal pedicle flap
Description: The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
Study NCT01353664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
Study NCT01880853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mammography
Description: participants were screened by mammography alone every year
Study NCT01880853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: participants were screened by ultrasound alone every year
Study NCT01880853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mammography and ultrasound
Description: Participants were screened by both mammography and ultrasound every year
Study NCT03034694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teledermatology consult
Description: teledermatology consult
Study NCT03034694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: The patient will undergo imaging but this report will not be put into the chart.
Study NCT02345941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent Action Report
Description: Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
Study NCT02345941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Action Report
Description: Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
Study NCT02345941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent Portal
Description: Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
Study NCT02345941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Portal
Description: Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
Study NCT02857322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Accompanying patient's specific perioperative
Study NCT00215618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine Balloon Therapy
Description: UBT with post procedure curettage
Study NCT00215618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine Balloon Therapy
Description: UBT without post procedure curettage
Study NCT01967043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
Study NCT02249715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway Multiway deep TMS device (two channels)
Study NCT04007484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoperfusion
Description: Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
Study NCT01834495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon expandable stent
Description: provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
Study NCT01834495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self expandable stent
Description: provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection